Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma

Bone Marrow Transplantation volume 57, pages 837–839 (2022)Cite this article

Subjects

Peripheral blood autologous stem cell transplantation (PBSCT) is considered the standard consolidation treatment for refractory aggressive large B cell lymphoma (LBCL) in first complete remission (CR) [1], and it may also have a role for patients with chemosensitive LBCL without CR [2]. Additionally, PBSCT alone was retrospectively associated with better outcomes compared to chimeric antigen receptor T cell therapy (CAR-T) in patients with LBCL with partial remission (PR) after salvage therapy [3], despite ZUMA-7 trial may have recently suggested differently [4].

Nowadays, third-line standard treatment is based on CAR-T cells. The addition of a bridging therapy may be necessary to contain the disease progression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Data availability

The data that support the findings of this study are available from the corresponding author, EG, upon reasonable request.

References

  1. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:10. 1525–1552

    Article  Google Scholar 

  2. Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, et al. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood 2021;137:1416–23.

    Article  CAS  Google Scholar 

  3. Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant versus chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139:1330–9.

  4. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54.

  5. Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D’Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607–15.

    Article  CAS  Google Scholar 

  6. Chen YB, Li S, Fisher DC, Driscoll J, Del Rio C, Abramson J, et al. Phase II trial of tandem high-dose chemotherapy with autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation for patients with high-risk lymphoma. Biol Blood Marrow Transpl. 2015;21:1583–8.

    Article  CAS  Google Scholar 

  7. Crocchiolo R, Castagna L, Fürst S, El-Cheikh J, Faucher C, Oudin C, et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma. Bone Marrow Transpl. 2013;48:249–52.

    Article  CAS  Google Scholar 

  8. Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, et al. Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Investig. 2020;130:6021–33.

    Article  CAS  Google Scholar 

  9. Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019;134:626–35.

    Article  CAS  Google Scholar 

  10. Wu J, Meng F, Cao Y, Zhang Y, Zhu X, Wang N, et al. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer J. 2021;11:131.

    Article  Google Scholar 

  11. Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776–87.

    Article  CAS  Google Scholar 

  12. Liévin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transpl. 2022 https://doi.org/10.1038/s41409-021-01526-0. Epub ahead of print. PMID: 35094012.

Download references

Acknowledgements

We acknowledge the support of “Centro di Ricerca sulle cellule staminali emopoietiche e le terapie cellulari “Università Cattolica del Sacro Cuore, Roma” research funding.

Author information

Author notes

  1. These authors contributed equally: Eugenio Galli, Federica Sorà.

Authors and Affiliations

  1. Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy

    Eugenio Galli, Federica Sorà, Stefan Hohaus, John Marra, Alberto Fresa, Patrizia Chiusolo, Luca Laurenti, Luciana Teofili, Nicola Piccirillo, Andrea Bacigalupo & Simona Sica

  2. Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

    Eugenio Galli, Federica Sorà, Stefan Hohaus, Silvia Bellesi, Francesco Autore, Elisabetta Metafuni, Idanna Innocenti, Maria Assunta Limongiello, Sabrina Giammarco, Lucia Leccisotti, Andrea Guarneri, Patrizia Chiusolo, Luca Laurenti, Luciana Teofili, Nicola Piccirillo, Andrea Bacigalupo & Simona Sica

Authors
  1. Eugenio Galli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federica Sorà
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Hohaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Bellesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Autore
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisabetta Metafuni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Idanna Innocenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John Marra
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alberto Fresa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Maria Assunta Limongiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sabrina Giammarco
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lucia Leccisotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Andrea Guarneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Patrizia Chiusolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Luca Laurenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Luciana Teofili
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Nicola Piccirillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Andrea Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Simona Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EG and SH prepared the manuscript; EG, FS, SH and SS designed the study and performed the revision of the literature; SB was responsible for flow cytometry analysis; JM revised the manuscript; LL and AG revised PET-CT scans; LLA, II. FA, AF, MAL, EM, SG, PC and AB revised the paper and contributed to patients’ management.

Corresponding author

Correspondence to Eugenio Galli.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galli, E., Sorà, F., Hohaus, S. et al. Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. Bone Marrow Transplant 57, 837–839 (2022). https://doi.org/10.1038/s41409-022-01632-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01632-7

Search

Advanced search

Quick links